CONTEXT: The aberrant processing of salience is thought to be a fundamental factor underlying psychosis. Cannabis can induce acute psychotic symptoms, and its chronic use may increase the risk of schizophrenia. We investigated whether its psychotic effects are mediated through an influence on attentional salience processing. OBJECTIVE: To examine the effects of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) on regional brain function during salience processing. DESIGN: Volunteers were studied using event-related functional magnetic resonance imaging on 3 occasions after administration of Δ9-THC, CBD, or placebo while performing a visual oddball detection paradigm that involved allocation of attention to infrequent (oddball) stimuli within a string of frequent (standard) stimuli. SETTING: University center. PARTICIPANTS: Fifteen healthy men with minimal previous cannabis use. MAIN OUTCOME MEASURES: Symptom ratings, task performance, and regional brain activation. RESULTS: During the processing of oddball stimuli, relative to placebo, Δ9-THC attenuated activation in the right caudate but augmented it in the right prefrontal cortex. Δ9-Tetrahydrocannabinol also reduced the response latency to standard relative to oddball stimuli. The effect of Δ9-THC in the right caudate was negatively correlated with the severity of the psychotic symptoms it induced and its effect on response latency. The effects of CBD on task-related activation were in the opposite direction of those of Δ9-THC; relative to placebo, CBD augmented left caudate and hippocampal activation but attenuated right prefrontal activation. CONCLUSIONS: Δ9-Tetrahydrocannabinol and CBD differentially modulate prefrontal, striatal, and hippocampal function during attentional salience processing. These effects may contribute to the effects of cannabis on psychotic symptoms and on the risk of psychotic disorders.
CONTEXT: The aberrant processing of salience is thought to be a fundamental factor underlying psychosis. Cannabis can induce acute psychotic symptoms, and its chronic use may increase the risk of schizophrenia. We investigated whether its psychotic effects are mediated through an influence on attentional salience processing. OBJECTIVE: To examine the effects of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) on regional brain function during salience processing. DESIGN: Volunteers were studied using event-related functional magnetic resonance imaging on 3 occasions after administration of Δ9-THC, CBD, or placebo while performing a visual oddball detection paradigm that involved allocation of attention to infrequent (oddball) stimuli within a string of frequent (standard) stimuli. SETTING: University center. PARTICIPANTS: Fifteen healthy men with minimal previous cannabis use. MAIN OUTCOME MEASURES: Symptom ratings, task performance, and regional brain activation. RESULTS: During the processing of oddball stimuli, relative to placebo, Δ9-THC attenuated activation in the right caudate but augmented it in the right prefrontal cortex. Δ9-Tetrahydrocannabinol also reduced the response latency to standard relative to oddball stimuli. The effect of Δ9-THC in the right caudate was negatively correlated with the severity of the psychotic symptoms it induced and its effect on response latency. The effects of CBD on task-related activation were in the opposite direction of those of Δ9-THC; relative to placebo, CBD augmented left caudate and hippocampal activation but attenuated right prefrontal activation. CONCLUSIONS: Δ9-Tetrahydrocannabinol and CBD differentially modulate prefrontal, striatal, and hippocampal function during attentional salience processing. These effects may contribute to the effects of cannabis on psychotic symptoms and on the risk of psychotic disorders.
Authors: Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij Journal: Psychopharmacology (Berl) Date: 2012-03-09 Impact factor: 4.530
Authors: R Androvicova; J Horacek; J Tintera; J Hlinka; J Rydlo; D Jezova; M Balikova; T Hlozek; P Miksatkova; M Kuchar; M Roman; P Tomicek; F Tyls; M Viktorinova; T Palenicek Journal: Psychopharmacology (Berl) Date: 2017-04-12 Impact factor: 4.530
Authors: Carmen Walter; Bruno G Oertel; Lisa Felden; Christian A Kell; Ulrike Nöth; Johannes Vermehren; Jochen Kaiser; Ralf Deichmann; Jörn Lötsch Journal: Neuropsychopharmacology Date: 2015-10-30 Impact factor: 7.853
Authors: Hedy Kober; Elise E DeVito; Cameron M DeLeone; Kathleen M Carroll; Marc N Potenza Journal: Neuropsychopharmacology Date: 2014-04-07 Impact factor: 7.853
Authors: Roger Hudson; Justine Renard; Christopher Norris; Walter J Rushlow; Steven R Laviolette Journal: J Neurosci Date: 2019-09-30 Impact factor: 6.167